Purpose
To conduct a review of active United States–based clinical trials investigating preventative,
symptom resolution, and disease-modifying therapies for osteoarthritis (OA).
Methods
We conducted a review of currently active clinical trials for OA using data obtained
from the ClinicalTrials.gov database as of August 2020. The inclusion criteria were active studies registered
in the United States that involved the prevention, symptom resolution, or disease
modification of OA. Descriptive statistics were recorded and summarized.
Results
A total of 3,859 clinical trials were identified, and 310 were included in the final
analysis. Of the currently active trials, 89% (n = 275) targeted symptom resolution
in patients with existing OA, 6% (n = 19) targeted OA disease-modifying therapeutics,
and 5% (n = 16) targeted the prevention of OA in high-risk patients (P < .001). Primary interventions included medical devices (44%, n = 137), pharmaceutical
drugs (14%, n = 42), surgical procedures (14%, n = 42), cellular biologics (13%, n =
41), and behavioral therapies (13%, n = 41). There was a significantly higher number
of disease-modifying therapeutics for cellular biologics than pharmaceutical drugs
(30% vs 14%) (P = .015). Most trials targeted the knee joint (63%, P = .042), with 38% of all trials evaluating joint arthroplasty. There were no significant
differences between private sector and government funding sources (43% and 49%, respectively)
(P = .288), yet there was a significantly lower rate of funding from industry (8%) (P = .026).
Conclusions
There was a significantly higher number of clinical trials investigating symptomatic
resolution therapy (89%) for existing OA in comparison to preventative (5%) and disease-modifying
(6%) therapies. The most common interventions involved medical devices and joint replacement
surgery, with the knee joint accounting for more than 60% of the current clinical
trials for OA. There was a significantly higher number of disease-modifying therapeutics
for cellular biologics than pharmaceutical drugs. Funding of clinical trials was split
between the private sector and government, with a low rate of reported funding from
industry partners.
Clinical Relevance
Identifying existing needs in the current market may help increase rates of research
funding or optimize current funding pathways, in this study, specifically for targeting
unaddressed focus areas in OA research. Our systematic review highlights the potential
need for additional research and development regarding OA preventative and disease-modifying
therapies.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to ArthroscopyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Osteoarthritis.Lancet. 2019; 393: 1745-1759
- National and state medical expenditures and lost earnings attributable to arthritis and other rheumatic conditions—United States, 2003.MMWR Morb Mortal Wkly Rep. 2007; 56: 4-7
- Non-surgical management of early knee osteoarthritis.Knee Surg Sports Traumatol Arthrosc. 2012; 20: 436-449
- Viscosupplementation: Therapeutic mechanisms and clinical potential in osteoarthritis of the knee.J Am Acad Orthop Surg. 2000; 8: 277-284
- Hallmarks in the history and development of total hip arthroplasty.Surg Innov. 2020; 27: 691-694
Mahoney O, Kinsey T, Sodhi N, et al. Improved component placement accuracy with robotic-arm assisted total knee arthroplasty [published online August 31, 2020]. J Knee Surg. https://doi.org/10.1055/s-0040-1715571.
- Current perspectives on biological approaches for osteoarthritis.Ann N Y Acad Sci. 2017; 1410: 26-43
- The role of orthobiologics in the management of osteoarthritis and focal cartilage defects.Orthopedics. 2019; 42: 66-73
- An update on the pathophysiology of osteoarthritis.Ann Phys Rehabil Med. 2016; 59: 333-339
- Regenerative potential of mesenchymal stem cells for the treatment of knee osteoarthritis and chondral defects: A systematic review and meta-analysis.Arthroscopy. 2021; 37: 362-378
- Orthopaedic trauma in the developing world: Where are the gaps in research and what can be done?.J Orthop Trauma. 2018; 32: S43-S46
- Comparing National Institutes of Health funding of emergency medicine to four medical specialties.Acad Emerg Med. 2011; 18: 1001-1004
- A ten-year analysis of the research funding program of the orthopaedic trauma association.J Bone Joint Surg Am. 2013; 95: e1421-e1426
- Post-traumatic osteoarthritis: From mouse models to clinical trials.Nat Rev Rheumatol. 2013; 9: 485-497
- Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement.BMJ. 2009; 339: b2535
- Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement.Ann Intern Med. 2009; 151 (W264): 264-269
- Epidemiology of posttraumatic osteoarthritis.J Athl Train. 2017; 52: 491-496
- Osteoarthritis.Nat Rev Dis Primers. 2016; 2: 16072
- Early osteoarthritis.Knee Surg Sports Traumatol Arthrosc. 2012; 20: 399-400
- The symptoms of osteoarthritis and the genesis of pain.Med Clin North Am. 2009; 93 (xi): 83-100
- Obesity is associated with an increased prevalence of glenohumeral osteoarthritis and arthroplasty: A cohort study.Orthop Clin North Am. 2020; 51: 259-264
- Sports-specialized intensive training and the risk of injury in young athletes: A clinical case-control study.Am J Sports Med. 2015; 43: 794-801
- Sport specialization's association with an increased risk of developing anterior knee pain in adolescent female athletes.J Sport Rehabil. 2015; 24: 31-35
- Patellofemoral chondral defect in a preadolescent skier: A case report in early sport specialization.Int J Sports Phys Ther. 2018; 13: 131-136
- Current and future impact of osteoarthritis on health care: A population-based study with projections to year 2032.Osteoarthritis Cartilage. 2014; 22: 1826-1832
- The individual and socioeconomic impact of osteoarthritis.Nat Rev Rheumatol. 2014; 10: 437-441
- The economic burden of disabling hip and knee osteoarthritis (OA) from the perspective of individuals living with this condition.Rheumatology (Oxford). 2005; 44: 1531-1537
- The personal and national costs of lost labour force participation due to arthritis: An economic study.BMC Public Health. 2013; 13: 188
- Osteoarthritis and the risk of cardiovascular disease: A meta-analysis of observational studies.Sci Rep. 2016; 6: 39672
- Increased risk of stroke in patients with osteoarthritis: A population-based cohort study.Osteoarthritis Cartilage. 2017; 25: 1026-1031
- Association between osteoarthritis and cardiovascular disease: Systematic review and meta-analysis.Eur J Prev Cardiol. 2016; 23: 938-946
- Yet more evidence that osteoarthritis is not a cartilage disease.Ann Rheum Dis. 2006; 65: 1261-1264
- The role of atherosclerosis in osteoarthritis.Best Pract Res Clin Rheumatol. 2017; 31: 613-633
- Projections of US prevalence of arthritis and associated activity limitations.Arthritis Rheum. 2006; 54: 226-229
- Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: A systematic analysis for the Global Burden of Disease Study 2015.Lancet. 2016; 388: 1545-1602
- Posttraumatic osteoarthritis: A first estimate of incidence, prevalence, and burden of disease.J Orthop Trauma. 2006; 20: 739-744
- The long-term consequence of anterior cruciate ligament and meniscus injuries: Osteoarthritis.Am J Sports Med. 2007; 35: 1756-1769
- High prevalence of osteoarthritis 14 years after an anterior cruciate ligament tear in male soccer players: A study of radiographic and patient relevant outcomes.Ann Rheum Dis. 2004; 63: 269-273
- High prevalence of knee osteoarthritis, pain, and functional limitations in female soccer players twelve years after anterior cruciate ligament injury.Arthritis Rheum. 2004; 50: 3145-3152
- High rates of osteoarthritis develop after anterior cruciate ligament surgery: An analysis of 4108 patients.Am J Sports Med. 2018; 46: 2011-2019
- Elevated plasma and synovial fluid interleukin-8 and interleukin-18 may be associated with the pathogenesis of knee osteoarthritis.Knee. 2020; 27: 26-35
- Pathogenesis of osteoarthritis: Risk factors, regulatory pathways in chondrocytes, and experimental models.Biology (Basel). 2020; 9: 194
- Intra-articular cellular therapy for osteoarthritis and focal cartilage defects of the knee: A systematic review of the literature and study quality analysis.J Bone Joint Surg Am. 2016; 98: 1511-1521
- Concentrated bone marrow aspirate for the treatment of chondral injuries and osteoarthritis of the knee: A systematic review of outcomes.Orthop J Sports Med. 2016; 4 (2325967115625481)
- Cell-surface markers identify tissue resident multipotential stem/stromal cell subsets in synovial intimal and sub-intimal compartments with distinct chondrogenic properties.Osteoarthritis Cartilage. 2019; 27: 1831-1840
- Blood-induced joint damage: The devastating effects of acute joint bleeds versus micro-bleeds.Cartilage. 2013; 4: 313-320
- Inflammatory mediators in osteoarthritis: A critical review of the state-of-the-art, current prospects, and future challenges.Bone. 2016; 85: 81-90
- Characterization of growth factors, cytokines, and chemokines in bone marrow concentrate and platelet-rich plasma: A prospective analysis.Am J Sports Med. 2019; 47: 2174-2187
- Parallel discovery of Alzheimer's therapeutics.Sci Transl Med. 2014; 6: 241cm5
- Commercializing biomedical research through securitization techniques.Nat Biotechnol. 2012; 30: 964-975
- Personalized medicine for osteoarthritis: Where are we now?.Ther Adv Musculoskelet Dis. 2013; 5: 67-75
- An FDA perspective on the regulatory implications of complex signatures to predict response to targeted therapies.Clin Cancer Res. 2017; 23: 1368-1372
- Machine-learning and stochastic tumor growth models for predicting outcomes in patients with advanced non-small-cell lung cancer.JCO Clin Cancer Inform. 2019; 3: 1-11
Article Info
Publication History
Published online: March 30, 2021
Accepted:
March 23,
2021
Received:
January 8,
2021
See commentary on page 2640Footnotes
The authors report the following potential conflicts of interest or sources of funding: G.M. is a member of the Arthroscopy Editorial Board and committee member of the International Society of Arthroscopy, Knee Surgery and Orthopaedic Sports Medicine . J.C. is a consultant for Smith & Nephew, Arthrex , ConMed, and Ossur, outside the submitted work. R.F.L. is a consultant for Smith & Nephew, Arthrex, and Ossur and receives royalties from Smith & Nephew, Arthrex, and Ossur. Full ICMJE author disclosure forms are available for this article online, as supplementary material.
Identification
Copyright
© 2021 by the Arthroscopy Association of North America
